These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: The in-vitro activity of CP-62,993 against Haemophilus influenzae, Branhamella catarrhalis, staphylococci and streptococci.
    Author: Dunkin KT, Jones S, Howard AJ.
    Journal: J Antimicrob Chemother; 1988 Apr; 21(4):405-11. PubMed ID: 2837451.
    Abstract:
    The in-vitro activity of a new macrolide antibiotic CP-62,993 (Pfizer Ltd) was determined for 420 bacterial isolates, comprising 150 Haemophilus influenzae, 48 Branhamella catarrhalis, 50 Staphylococcus aureus, 50 coagulase negative staphylococci, 50 beta-haemolytic streptococci, 50 Streptococcus pneumoniae and 22 oral streptococci. CP-62,993 was compared with erythromycin and penicillin (ampicillin in the case of H. influenzae). The MICs of CP-62,993 were found to be lower than those of erythromycin for the two Gram-negative species tested: this was particularly marked in the case of H. influenzae where a ten-fold difference in the MIC50 was observed (CP-62,993, 0.25 mg/l, erythromycin 2 mg/l). In general MICs of CP-62,993 were two-fold higher than those of erythromycin for the Gram-positive species studied, with the exception of the oral streptococci which were equally susceptible (MIC50 0.03 mg/l) to both macrolides. Activity similar to that of erythromycin was observed against Str. pneumoniae (MIC values 0.015-0.12 mg/l), Staph. aureus (MIC 0.12-1 mg/l) and beta-haemolytic streptococci (MIC 0.06-4 mg/l). Incubation in a CO2 enriched atmosphere decreased activity of both erythromycin and CP-62,993. The effect was more marked for CP-62,993, the MIC50s of all groups of organisms being increased four-fold when they were incubated in the presence of 5 or 10% CO2.
    [Abstract] [Full Text] [Related] [New Search]